UK Denies Pfizer’s Bid To Clear Path For Biosimilar Bevacizumab
Pfizer cannot get a UK Arrow declaration clearing it of infringement of pending bevacizumab patent applications through the biosimilar it plans to import from Belgium because Roche has already de-designated the UK parts of the applications.
You may also be interested in...
Trastuzumab, rituximab and bevacizumab are slated for launch later this year as Pfizer builds out its biosimilar oncology offering.
Samsung Bioepis and Fujifilm Kyowa Kirin Biologics have won a patent battle that should allow them to launch their biosimilar versions of AbbVie’s Humira in the UK and may also have implications for other companies wanting to clear away legal uncertainties.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.